Mixed Phase III results for Dainippon Sumitomo's antipsychotic lurasidone
This article was originally published in Scrip
Dainippon Sumitomo Pharma's once-daily atypical antipsychotic lurasidone has shown mixed results in patients with schizophrenia, where one out of the three doses investigated in its first Phase III clinical trial met the primary endpoint. The results were presented at the annual meeting of the American Psychiatric Association in San Francisco.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.